‹ Back

 

MedTech Industry Pulse: May 2026 Roundup

May 2026 | By Cahir Solutions

 

May brought another important mix of regulatory, market, and regional developments for MedTech teams to watch. This month’s standout theme was the growing link between product availability, digital health oversight, and market-specific compliance planning, as regulators in the US, EU, and UK pushed industry toward more proactive execution.

 

US regulatory focus

The FDA’s device updates in May reinforced how quickly post-market actions can affect both manufacturers and providers. CDRH highlighted several safety-related developments during the month, including a Boston Scientific pacemaker correction and a convenience kit recall, while the agency also added neurosurgical patties to the medical device shortage list and issued recommendations to healthcare providers on prioritization and conservation strategies during the shortage.  The manufacturing disruption affecting the supply of these devices is expected to affect patient care and may require changes in the clinical management of patients undergoing neurosurgery or microsurgery. The FDA currently expects the shortage to continue through the end of 2026 and recommends that health care providers conserve neurosurgical patties, sponges, and strips when possible.

 

At the same time, the FDA’s 2026 device framework continues to reflect the transition to the Quality Management System Regulation, with the agency stating that after February 2, 2026 it would no longer use certain legacy inspection documents tied to the former Quality System Regulation approach.   For digital health and software developers, the broader US policy direction remains notable as updated FDA guidance has expanded the scope of certain low-risk general wellness products and clarified boundaries for some clinical decision support software, creating opportunity for some developers while leaving a high bar in place for products that cross into regulated medical use. FDA’s new Human Factors marketing guidance sharpens expectations around when and how MedTech companies must show that their user interfaces can be used safely by real-world users—and it does this through a structured, risk-based framework tied directly to marketing submissions.

 

Global regulatory updates

In Europe, the broader MDR and IVDR framework remains the defining backdrop for market access and compliance planning. The European Commission continues to position the new regulations as a modernization of the legal framework for medical devices and in vitro diagnostics, while industry pressure remains high because notified body capacity and submission quality still shape real-world timelines.

The practical message for manufacturers is that technical documentation quality, classification accuracy, and early engagement remain essential. Even where policymakers are considering targeted risk-based adjustments, the overall direction in Europe is still toward a more structured, evidence-driven, and resource-intensive regulatory model rather than a meaningful rollback of requirements.

 

Emerging AI regulations

Artificial intelligence is becoming a more visible regulatory issue for MedTech companies, especially those developing software-enabled devices, clinical decision support tools, and adaptive algorithms. In the EU, the AI Act remains the most important horizontal framework, with phased implementation continuing through 2026 and beyond, while policymakers are also considering how its obligations should interact with MDR and IVDR requirements for medical devices.

For AI-enabled medical devices, the practical challenge is no longer just proving core safety and performance. Teams increasingly need to prepare for expectations around risk management, human oversight, transparency, cybersecurity, lifecycle monitoring, and documentation that explains how AI functions within the product and how changes will be controlled over time.

In the UK, AI as a medical device is still being addressed largely through the broader software-as-a-medical-device reform agenda rather than a fully separate AI law. The MHRA’s ongoing work on software and AI as a medical device shows that UK requirements are also moving toward more explicit lifecycle regulation, classification clarity, and stronger post-market oversight for AI-driven products.

 

UK and regional developments

In the UK, the MHRA published a draft amendment to the UK Medical Devices Regulations 2002 on 8 May 2026, signaling another major step in the evolution of the post-Brexit framework. The draft includes an international reliance pathway, a mandatory unique device identifier system, and a more risk-proportionate classification framework, with stakeholder feedback open until 19 June 2026 and implementation expected in stages beginning in 2027.

These proposals matter because they point toward a UK system that is trying to balance global alignment with domestic control. For manufacturers, that means regulatory strategy for Great Britain can no longer be treated as a simple extension of EU planning, especially for software-based devices, higher-risk products, and companies relying on traceability and post-market surveillance systems to support broader commercialization plans.

 

What this means

For MedTech stakeholders, May’s developments underscore a common message: resilience, evidence, and operational readiness now need to extend beyond premarket approvals. Device shortages, digital health policy refinement, emerging AI rules, and UK reforms show that market success increasingly depends on supply continuity, careful product positioning, and the ability to adapt quality and regulatory systems across jurisdictions.

This affects portfolio strategy, regulatory planning, commercialization timing, and post-market governance all at once. Teams that treat regulatory change as a cross-functional business issue rather than a narrow compliance issue will be in a stronger position to respond as expectations continue to evolve across the US, Europe, and the UK.

 

Thank you for reading this month’s edition. We’ll be back in June with the latest updates, insights, and developments in MedTech and Digital Health.

 

 

How CAHIR Solutions can help

CAHIR Solutions can help teams respond to these shifts by aligning regulatory strategy, quality systems, and commercialization planning across markets. For organizations working on software-enabled devices, AI-enabled technologies, hospital-based systems, or products facing heightened scrutiny around supply continuity, evidence generation, or UK and EU market access, CAHIR can support gap assessments, documentation readiness, regulatory roadmap development, and cross-functional execution so programs move forward with more confidence and less friction.